1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Lou Gehrig’s Disease - Pipeline Insight, 2021

Lou Gehrig’s Disease - Pipeline Insight, 2021

  • February 2021
  • 60 pages
  • ID: 6022084
  • Format: PDF
  • Delve Insight


Table of Contents

“Lou Gehrig’s disease – Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Lou Gehrig’s disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Lou Gehrig’s disease Understanding

Lou Gehrig’s disease: Overview
Lou Gehrig’s disease is often called Amyotrophic Lateral Sclerosis (ALS). ALS is a progressive, degenerative disease that destroys the nerve cells that control voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking.It affects nerves in the brain and spinal cord that control muscles. The result is progressive muscle weakness and incoordination, causing difficulty with mobility, speaking, swallowing and breathing. Gradually the body becomes paralyzed, which means that the muscles no longer work. The exact cause is unknown, but environmental and genetic factors may be involved. ALS tends to strike in mid-life between the ages of 40 and 60, but others can develop the disease. ALS can be classified as either sporadic or familial. Sporadic ALS occurs randomly, there is no clear factor or cause. Familial ALS is inherited due to change in gene.

"Lou Gehrig’s disease - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lou Gehrig’s disease pipeline landscape is provided which includes the disease overview and Lou Gehrig’s disease treatment guidelines. The assessment part of the report embraces, in depth Lou Gehrig’s disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lou Gehrig’s disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
? The companies and academics are working to assess challenges and seek opportunities that could influence Lou Gehrig’s disease R&D. The therapies under development are focused on novel approaches to treat/improve Lou Gehrig’s disease.

Lou Gehrig’s disease Emerging Drugs Chapters
This segment of the Lou Gehrig’s disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lou Gehrig’s disease Emerging Drugs
? BIIB067: Ionis Pharmaceuticals, Inc
BIIB067 (Tofersen) is a second generation antisense oligonucleotide designed to reduce the production of superoxide dismutase 1 (SOD1), the cause of a genetic form of ALS, referred to as SOD1-ALS, that results from mutations in the SOD1 gene. Tofersen is currently in a Phase 3 clinical trial in SOD1-ALS patients led by Ionis Pharmaceuticals, Inc in collaboration with Biogen.

? Arimoclomol: Orphazyme
Orphazyme is developing arimoclomol in four indications: Niemann-Pick disease Type C (NPC), Gaucher disease, Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM). Arimoclomol has been shown to increase the production of cell protective HSPs. This increase in the production of naturally occurring HSPs inside the cells, reduces protein misfolding and aggregation and improves lysosomal function. Arimoclomol is currently in its phase III of development.

? ALZT-OP1a: AZTherapies, Inc.
AZTherapies, Inc. a biopharmaceutical company leading the advanced clinical trials to treat neuroinflammatory diseases, ALZT-OP1a is currently in Phase 2a stage of development examining the safety and efficacy in patients with mild- to moderate-stage Amyotrophic Lateral Sclerosis (ALS). ALZT-OP1a is the company’s proprietary inhaled formulation of cromolyn, engineered to improve blood brain barrier permeability and bioavailability.

? RNS60: Revalesio Corporation.
RNS60 is a leading clinical drug candidate to treat amyotrophic lateral sclerosis (ALS) and other neurological diseases. It can be administered by IV infusion or inhalation (nebulization).RNS60 is currently being tested in a placebo-controlled, multicenter ALS Phase 2 study. RNS60 acts on mitochondria and activates intracellular signaling pathways that have anti-inflammatory effects and promote cellular survival and differentiation. Thereby, RNS60 protects neurons and oligodendrocytes, and helps the immune system restore homeostasis through modulation of immune cell activity in the central nervous system and throughout the body.
Further product details are provided in the report……..

Lou Gehrig’s disease: Therapeutic Assessment
This segment of the report provides insights about the different Lou Gehrig’s disease drugs segregated based on following parameters that define the scope of the report, such as:
? Major Players in Lou Gehrig’s disease
There are approx. 30+ key companies which are developing the therapies for Lou Gehrig’s disease. The companies which have their Lou Gehrig’s disease drug candidates in the most advanced stage, i.e. phase III include, Ionis Pharmaceuticals Inc.

? Phases
report covers around 30+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II and phase I/II )
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

? Route of Administration
Lou Gehrig’s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Inhalation
? Molecule Type

Products have been categorized under various Molecule types such as
• Peptides
• Small molecule
• Oligonucleotides
• Gene Therapy
? Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lou Gehrig’s disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lou Gehrig’s disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lou Gehrig’s disease drugs.

Lou Gehrig’s disease Report Insights
• Lou Gehrig’s disease Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lou Gehrig’s disease Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Lou Gehrig’s disease drugs?
• How many Lou Gehrig’s disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lou Gehrig’s disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to Lou Gehrig’s disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lou Gehrig’s disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Ionis Pharmaceuticals Inc.
• AZTherapies Inc.
• Revalesio Corporation.
• AB science
• Biogen
• Hoffmann-La Roche
• Mitsubishi Tanabe Pharma Development America Inc.
• Orphazyme
• Q Therapeutics, Inc.
• Genuv Inc.
• Orion Corporation
• AL-S Pharma
• Immunity Pharma Ltd.
• Everfront Biotech Co., Ltd.

Key Products
• IPL344
• BIIB078
• MT-1186
• Levosimendan
• HK-001
• IPL344
• Arimoclomol
• Dexpramipexole
• BIIB078
• Olesoxime
• Masitinib

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Down Syndrome (Genetic Disorders) - Drugs in Development, 2021

  • $ 2000
  • March 2021
  • 100 pages

Down Syndrome (Genetic Disorders) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Down Syndrome - Drugs in Development, 2021, provides an overview ...

  • World
  • Dementia
  • Pharmaceutical
  • Industry analysis
  • Diagnostic Imaging Density
  • Drug Approval


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on